0000000000284975

AUTHOR

Cristian Soza-ried

showing 2 related works from this author

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases

2021

Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods: Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional …

0301 basic medicinebusiness.industrymedicine.medical_treatmentBone metastasisBisphosphonatemedicine.disease03 medical and health sciencesProstate cancer030104 developmental biology0302 clinical medicineTherapeutic index030220 oncology & carcinogenesisRadionuclide therapymedicineDosimetryRadiology Nuclear Medicine and imagingNuclear medicinebusinessProspective cohort studyBlood drawingJournal of Nuclear Medicine
researchProduct

[18F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease.

2020

Introduction Degeneration of dopaminergic, nigrostriatal neurons is the hallmark of Parkinson disease (PD), and PET quantification of dopamine transporters is a widely accepted method for differential diagnosis between idiopathic PD and essential tremor. [18F]PR04.MZ is a new PET tracer with excellent imaging properties allowing for precise quantification of striatal and extrastriatal dopamine transporter. Here we describe our initial experience with [18F]PR04.MZ PET/CT in a larger cohort of healthy controls and PD patients as a proof-of-concept study for this tracer. Methods Eighteen healthy subjects, 19 early PD patients (Hoehn-Yahr I–II), and 13 moderate-advanced PD patients (Hoehn-Yahr …

MaleDopamineCaudate nucleusPET imagingSubstantia nigra[18F]PR04.MZ030218 nuclear medicine & medical imagingCohort Studies03 medical and health sciences0302 clinical medicineDopaminePositron Emission Tomography Computed TomographyMedicineHumansRadiology Nuclear Medicine and imagingdopamine transporterDopamine transporterAgedNeuronsDopamine Plasma Membrane Transport ProteinsbiologyEssential tremorbusiness.industryPars compactaPutamenDopaminergicParkinson DiseaseGeneral MedicineOriginal ArticlesMiddle Agedmedicine.diseaseSubstantia Nigranervous system030220 oncology & carcinogenesisbiology.proteinmovement disordersFemalebusinessNuclear medicinemedicine.drugClinical nuclear medicine
researchProduct